WO2000053228A3 - Utilisation d'huile essentielle de niaouli comme agent favorisant la penetration transdermique - Google Patents

Utilisation d'huile essentielle de niaouli comme agent favorisant la penetration transdermique Download PDF

Info

Publication number
WO2000053228A3
WO2000053228A3 PCT/IT2000/000079 IT0000079W WO0053228A3 WO 2000053228 A3 WO2000053228 A3 WO 2000053228A3 IT 0000079 W IT0000079 W IT 0000079W WO 0053228 A3 WO0053228 A3 WO 0053228A3
Authority
WO
WIPO (PCT)
Prior art keywords
niaouli
drug
steroidal
essential oil
transdermal
Prior art date
Application number
PCT/IT2000/000079
Other languages
English (en)
Other versions
WO2000053228A2 (fr
Inventor
Marco Fabrizio Saettone
Boris Giannaccini
Daniela Monti
Enrico Boldrini
Pietro Bianchini
Original Assignee
Farmigea Spa
Marco Fabrizio Saettone
Boris Giannaccini
Daniela Monti
Enrico Boldrini
Pietro Bianchini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmigea Spa, Marco Fabrizio Saettone, Boris Giannaccini, Daniela Monti, Enrico Boldrini, Pietro Bianchini filed Critical Farmigea Spa
Priority to EP00911257A priority Critical patent/EP1159009A2/fr
Priority to AU33240/00A priority patent/AU3324000A/en
Publication of WO2000053228A2 publication Critical patent/WO2000053228A2/fr
Publication of WO2000053228A3 publication Critical patent/WO2000053228A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions permettant une administration transdermique et dermique de principes pharmaceutiquement actifs, en particulier des stéroïdes, par exemple des oestrogènes, des progestérones ou des anti-progestérones stéroïdiques, et des anti-inflammatoires non stéroïdiques (FANS), comme le diclofénac, le diclofénac d'ammonium diéthylique, le kétoprofène, le piroxicam, ou le nimesulide. L'essence naturelle connue sous le nom d'huile de niaouli favorise en effet la pénétration transcutanée et l'absorption du médicament. En plus de faciliter l'absorption de médicaments à un niveau systémique, les formulations contenant de l'huile de niaouli peuvent être utilisées dans des applications dermatologiques nécessitant une pénétration améliorée d'un médicament, par exemple un anti-inflammatoire stéroïdique ou non stéroïdique, à travers la couche cornée de l'épiderme. Cette invention concerne également des systèmes thérapeutiques d'administration transdermique (STT) renfermant de l'huile essentielle de niaouli comme agent favorisant la pénétration transdermique.
PCT/IT2000/000079 1999-03-10 2000-03-09 Utilisation d'huile essentielle de niaouli comme agent favorisant la penetration transdermique WO2000053228A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00911257A EP1159009A2 (fr) 1999-03-10 2000-03-09 Utilisation d'huile essentielle de niaouli comme agent favorisant la penetration transdermique
AU33240/00A AU3324000A (en) 1999-03-10 2000-03-09 Use of niaouli essential oil as transdermal permeation enhancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000151A IT1305303B1 (it) 1999-03-10 1999-03-10 Uso dell'olio essenziale di niaouli come promotore per la permeazionetransdermica.
ITRM99A000151 1999-03-10

Publications (2)

Publication Number Publication Date
WO2000053228A2 WO2000053228A2 (fr) 2000-09-14
WO2000053228A3 true WO2000053228A3 (fr) 2000-11-16

Family

ID=11406548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2000/000079 WO2000053228A2 (fr) 1999-03-10 2000-03-09 Utilisation d'huile essentielle de niaouli comme agent favorisant la penetration transdermique

Country Status (4)

Country Link
EP (1) EP1159009A2 (fr)
AU (1) AU3324000A (fr)
IT (1) IT1305303B1 (fr)
WO (1) WO2000053228A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
DE10053383A1 (de) * 2000-10-27 2002-05-08 Bionorica Arzneimittel Gmbh Verwendung von Terpenen als Enhancer der transmucosalen Resorption und Terpene enthaltende pharmazeutische Zubereitungen
DE10056011A1 (de) * 2000-11-11 2002-05-16 Beiersdorf Ag Hautfreundliches Wirkstoffpflaster zur insbesondere transdermalen Verabreichung ätherischer Öle
ITMI20041855A1 (it) * 2004-09-29 2004-12-29 Polichem Sa Composizioni farmaceutiche di alfa-diidroergocriptina per uso transdermico e-o transmucoso.
BRPI0914687A2 (pt) * 2008-06-24 2015-10-20 Intervet Int Bv preparação veterinária por derramamento, métodos para tratar condições inflamatórias e para administrar a preparação veterinária por derramamento, e, uso da preparação veterinária por derramamento
RU2686937C2 (ru) 2014-06-30 2019-05-06 Конинклейке Филипс Н.В. Прободержатель для биологических проб
US10232048B1 (en) * 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
EP3723729B8 (fr) * 2017-12-11 2023-11-01 Meat & Livestock Australia Limited Formulation analgésique transdermique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007901A1 (fr) * 1991-10-26 1993-04-29 Ian Flockhart Composition pour application locale
EP0744177A2 (fr) * 1995-05-23 1996-11-27 Gisela Hartwig Substance contenant au moins une huile essentielle et une provitamin, utile notamment dans la prévention et le traitement d'escarres
WO1999026589A2 (fr) * 1997-11-26 1999-06-03 Andrea Carnevali Preparation pour le traitement des brulures, des coups de soleil, des exulcerations, des ulceres et des irritations de la peau

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007901A1 (fr) * 1991-10-26 1993-04-29 Ian Flockhart Composition pour application locale
EP0744177A2 (fr) * 1995-05-23 1996-11-27 Gisela Hartwig Substance contenant au moins une huile essentielle et une provitamin, utile notamment dans la prévention et le traitement d'escarres
WO1999026589A2 (fr) * 1997-11-26 1999-06-03 Andrea Carnevali Preparation pour le traitement des brulures, des coups de soleil, des exulcerations, des ulceres et des irritations de la peau

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GALLE-HOFFMANN U AND KÖNIG WA: "Ätherische Öle, 3. Folge. Weitere Teebaumöle aus der Gattung Melaleuca", DEUTSCHE APOTHEKER ZEITUNG, vol. 139, no. 50, 16 December 1999 (1999-12-16), ISSN 0011-9857, pages 53-56 and 59-62, XP002145464 *
KALBITZ J, ET AL.: "Modulation der Wirkstoffpenetration in die Haut", PHARMAZIE, vol. 51, no. 9, 1996, ISSN 0031-7144, XP000621188 *
QUEVAUVILLER A AND PANOUSE-PERRIN J: "Exaltation du pouvoir anesthésique local de la cocaïne par l'essence de niaouli purifiée", ANESTHÉSIE ET ANALGÉSIE (PARIS), vol. 9, no. 3, 1952, ISSN 0003-3014, pages 421 - 426, XP000900443 *
QUEVAUVILLER A AND VU NGOC HUYEN: "Étude expérimentale des brûlures par l'acide fluorhydrique et de leur traitement. III) Traitement", THÉRAPIE (PARIS), vol. 31, no. 3, 1976, ISSN 0040-5957, pages 413 - 420, XP000923137 *

Also Published As

Publication number Publication date
IT1305303B1 (it) 2001-05-04
AU3324000A (en) 2000-09-28
WO2000053228A2 (fr) 2000-09-14
ITRM990151A1 (it) 2000-09-10
EP1159009A2 (fr) 2001-12-05

Similar Documents

Publication Publication Date Title
EP0974350B1 (fr) Preparation a usage externe comprenant du tranilast et processus de production de cette preparation
JP5506126B2 (ja) 経皮システムにおける加速した医薬の送達
US5686097A (en) Monoglyceride/lactate ester permeation enhancer for codelivery of steroids
EP2131813B1 (fr) Formulation pharmaceutique topique
JP2604097B2 (ja) 皮膚浸透増強剤としてソルビタンエステルを用いた経皮的に薬物を投与するための方法およびシステム
US20070190124A1 (en) Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070196457A1 (en) Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US20050187212A1 (en) Pharmaceutical composition for topical delivery of meloxicam
US20050186141A1 (en) Transdermal aerosol compositions
US20070196452A1 (en) Flux-enabling compositions and methods for dermal delivery of drugs
EP1959930A2 (fr) Compositions de fluidification et procede pour administrer par voie cutanee des medicaments
JPS5815910A (ja) 生物影響剤の皮膚浸透を高めるためのユ−カリプト−ル使用
AP2003002922A0 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition.
HUT74876A (en) Sexual steroid-containing transdermal therapeutic systems
AU4261097A (en) Compositions and methods for topical application of therapeutic agents
WO2006113505A3 (fr) Systemes d'apport de substances pharmaceutiques destines a des medicaments hydrophobes et compositions comprenant ces derniers
AU2006290487A1 (en) Topical film-forming monophasic formulations
WO1998002169A3 (fr) Nouvelles preparations pour l'administration de fluoxetine
WO2015191402A1 (fr) Nouveau gel pour administration topique d'ains destiné à apporter un soulagement à la douleur musculo-squelettique, et ses procédés de préparation
WO2000053228A3 (fr) Utilisation d'huile essentielle de niaouli comme agent favorisant la penetration transdermique
EP1968541A2 (fr) Compositions et procedes d'administration dermique de medicaments
JP3207212B2 (ja) 吸収促進剤およびこれを含有する外用剤
WO2006091719A3 (fr) Compositions et procedes ameliorant l'apport transdermique de medicaments et d'agents biologiques
ZA200506286B (en) Therapeutic agent for hemorrhoidal disease
CA2490325A1 (fr) Compositions d'aerosol transdermiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000911257

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000911257

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000911257

Country of ref document: EP